Icobrain.aria is reportedly the first AI software geared toward the detection and monitoring of amyloid-related imaging abnormalities (ARIAs) on brain MRI.
The Food and Drug Administration (FDA) has granted 510(k) clearance for icobrain.aria, an artificial intelligence (AI)-enabled software that may enhance the detection of amyloid-related imaging abnormalities (ARIAs) on brain MRI for patients being treated for Alzheimer’s disease.
Noting that ARIAs have been associated with recently approved disease-modifying agents for Alzheimer’s disease, Icometrix, the developer of icobrain.aria, said icobrain.aria is the first AI software dedicated to the diagnosis and monitoring of ARIAs in this patient population.
The images above reveal severe ARIA-E in a patient who presented with parenchymal edema. The AI-enabled software icobrain.aria, which was recently cleared by the FDA, demonstrated a 16 percent increase in sensitivity for ARIA-E and a 10 percent increase in sensitivity for ARIA-H, in a retrospective study published earlier this year in JAMA Network Open. (Images courtesy of JAMA Network Open.)
In a retrospective study published earlier this year in JAMA Network Open, icobrain.aria demonstrated a 16 percent increase in sensitivity for ARIA-E and a 10 percent increase in sensitivity for ARIA-H.
“New standardized tools are needed … to assist radiologists and treating clinicians in detecting and managing ARIA to optimize patient safety. I am excited that icobrain.aria has received FDA approval, clearing the way for wider use in clinical practice,” noted Stephen Salloway, M.D., the director of neurology and the Memory and Aging Program at Butler Hospital in Providence, R.I.
FDA Clears Ultrasound AI Detection for Pleural Effusion and Consolidation
June 18th 2025The 14th FDA-cleared AI software embedded in the Exo Iris ultrasound device reportedly enables automated detection of key pulmonary findings that may facilitate detection of pneumonia and tuberculosis in seconds.
Multinational Study Reaffirms Value of Adjunctive AI for Prostate MRI
June 16th 2025The use of adjunctive AI in biparametric prostate MRI exams led to 3.3 percent and 3.4 percent increases in the AUC and specificity, respectively, for clinically significant prostate cancer (csPCa) in a 360-person cohort drawn from 53 facilities.